ReviewLeukemia2022
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph
Review in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06928909 (Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi), which is not on this map. Cited by 2,391 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2,391citing papers in PubMed, 3 pooled it
552.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi
Who cites it
2,391 citing papers in PubMed, 3 syntheses or guidelines pooled it, 3,654 citations in OpenAlex.
- The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).International journal of cancer · 2026Guideline
- ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review.Medical oncology (Northwood, London, England) · 2026Pooled it
- Prognostic implications of myelodysplasia-related gene mutations inHaematologica · 2026Pooled it
- Immunophenotyping of Acute Myeloid Leukemia.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Enumeration of Benign and Malignant Plasmacytoid Dendritic Cells in Peripheral Blood and Bone Marrow by Flow-Cytometric Analysis.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Mutations in CHIP-associated genes at myeloid neoplasm diagnosis and risk of cardiovascular/cerebrovascular events.Annals of medicine · 2026Article
- Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes.Annals of medicine · 2026Article
- Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.Annals of medicine · 2026Article
- Isolated bilateral breast myeloid sarcoma: A rare case report.Radiology case reports · 2026Article
- KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations.European journal of haematology · 2026Article
- Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin.Leukemia · 2026Article
- Article
- Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.International journal of cancer · 2026Review
- Successful allogeneic hematopoietic stem cell transplantation in children with myeloid malignancies secondary to GATA2 deficiency using decitabine-containing busulfan conditioning.Bone marrow transplantation · 2026Article
- Multifocal Laryngotracheal Rosai-Dorfman Disease: 48-Month Remission After Surgical Resection.The Laryngoscope · 2026Article
- Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications.International journal of laboratory hematology · 2026Review
- Long-term mutational analysis, clonal metrics, and dynamics in patients with chronic idiopathic neutropenia.HemaSphere · 2026Article
- AI In Leukemia Diagnostics: Complementing the Pathologist's Role.International journal of laboratory hematology · 2026Review
- Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms.International journal of laboratory hematology · 2026Article
- MDS without clonal marker: when depth outperforms breadth.Leukemia · 2026Article
2,331 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
62 authors at 20 institutions in 14 countries.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jkhoury@unmc.edu.ORCID http://orcid.org/0000-0003-2621-3584
Eric SolaryDepartment of Hematology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France. eric.solary@gustaveroussy.fr.ORCID http://orcid.org/0000-0002-8629-1341
Oussama AblaDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Yassmine AkkariThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-3072-7388
Rita AlaggioPathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
Jane F ApperleyCentre for Haematology, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-1710-1794
Rafael BejarMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5603-4598
Emilio BertiUniversity of Milan, Fondazione Cà Granda, IRCCS, Ospedale Maggiore Policlinico, Milano, Italy.
Lambert BusqueService d'hématologie, oncologie et transplantation, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, QC, Canada.ORCID http://orcid.org/0000-0002-5375-3749
John K C ChanDepartment of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong.
Weina ChenDepartment of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-5638-4371
Xueyan ChenDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Wee-Joo ChngDepartment of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore.
John K ChoiDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0002-2861-0180
Isabel ColmeneroDepartment of Pathology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.ORCID http://orcid.org/0000-0001-6859-187X
Sarah E CouplandLiverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, UK.
Nicholas C P CrossFaculty of Medicine, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0001-5481-2555
Daphne De JongAmsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Pathology, Amsterdam, The Netherlands.
M Tarek ElghetanyDepartment of Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Emiko TakahashiDepartment of Pathology, Aichi Medical University Hospital, Nagakute, Japan.ORCID http://orcid.org/0000-0001-8284-567X
Jean-Francois EmileDepartment of Pathology, Ambroise Pare Hospital, AP-HP and Versailles SQY University, Boulogne, France.ORCID http://orcid.org/0000-0002-6073-4466
Judith FerryDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Linda FogelstrandDepartment of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg and Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden.
Michaela FontenayLaboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital and Université Paris Cité, CNRS, INSERM, Cochin Institute, Paris, France.
Ulrich GermingDepartment of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Sumeet GujralDepartment of Pathology, Tata Memorial Hospital, Mumbai, India.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0003-0196-2837
Claire HarrisonDepartment of Haematology, Guys and St Thomas' NHS Foundation Trust, London, UK.
Jennelle C HodgeIndiana University School of Medicine, Indianapolis, IN, USA.
Shimin HuDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7110-3814
Joop H JansenLab Hematology, Dept LABGK, Radboud University Medical Center, Nijmegen, The Netherlands.
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7829-5249
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1908-3307
Christian P KratzPediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0003-4120-5873
Xiao-Qiu LiDepartments of Pathology and Oncology, Fudan University, Shanghai, China.
Megan S LimDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Keith LoebSection of Pathology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8980-3202
Andrea MarcoglieseDepartment of Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Soheil MeshinchiPediatric Hematology and Oncology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Phillip MichaelsDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Kikkeri N NareshSection of Pathology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-3807-3638
Yasodha NatkunamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9816-1018
Reza NejatiDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA.
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Eric PadronMalignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-4707-7916
Keyur P PatelDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nikhil PatkarHematopathology Laboratory, Tata Memorial Hospital, Mumbai, India.ORCID http://orcid.org/0000-0001-9234-2857
Jennifer PicarsicPathology and Lab Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Uwe PlatzbeckerDepartment of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0003-1863-3239
Irene RobertsDepartment of Paediatrics, University of Oxford, Oxford, UK.
Anna SchuhDepartment of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-3938-8490
William SewellImmunology Division, Garvan Institute of Medical Research, Sydney, Australia.
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Prashant TembhareHematopathology Laboratory, Tata Memorial Hospital, Mumbai, India.ORCID http://orcid.org/0000-0002-9030-0415
Jeffrey TynerCell, Developmental & Cancer Biology Department, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-2133-0960
Srdan VerstovsekDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6912-8569
Wei WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6821-4556
Brent WoodDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Wenbin XiaoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8586-8500
Cecilia YeungSection of Pathology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6799-2022
Andreas HochhausHematology/Oncology, Universitätsklinikum Jena, Jena, Germany. andreas.hochhaus@med.uni-jena.de.ORCID http://orcid.org/0000-0003-0626-0834
The University of Texas MD Anderson Cancer Center · USFred Hutch Cancer Center · USTata Memorial Hospital · INBaylor College of Medicine · USUniversity of Oxford · GBAichi Medical University Hospital · JPAmsterdam University Medical Centers · NLAssistance Publique – Hôpitaux de Paris · FRBambino Gesù Children's Hospital · ITBeth Israel Deaconess Medical Center · USCentre National de la Recherche Scientifique · FRChildren's Hospital of Los Angeles · USCincinnati Children's Hospital Medical Center · USFox Chase Cancer Center · USFudan University · CNGarvan Institute of Medical Research · AUGuy's and St Thomas' NHS Foundation Trust · GBHarvard University · USHeinrich Heine University Düsseldorf · DEHôpital Maisonneuve-Rosemont · CA
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MAssessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemiaK08CA267058 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI XIAO, WENBIN · 2022 to 2025
$1.1MMedical Research Council MC_UU_12009/14NCI NIH HHS K08 CA267058NCI NIH HHS P30 CA008748Wellcome Trust
Abstract
The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.
Indexed as
Hematologic NeoplasmsHistiocytosisHumansWorld Health Organization
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06928909ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.